MedTrace Logo

Safety Study and Therapeutic Effects of Umbilical Cord Blood Treg on Autoimmune Diabetes

NCT02932826 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-03-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo expanded umbilical cord blood regulatory T cells on autoimmune diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

BIOLOGICAL

Umbilical Cord Blood Regulatory T cells Therapy

Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS

DRUG

Insulin

Treated according to routine clinical practice at the discretion of the treating physician

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Zhiguang Zhou, MD/PhD · Second Xiangya Hospital of Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2025-06-30
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02932826 on ClinicalTrials.gov